Ignyta Inc. (RXDX:NASDAQ)

Ignyta Inc. (RXDX:NASDAQ)

Ignyta Inc. (RXDX:NASDAQ) has a $420M market cap. Ignyta takes a targeted approach to oncology, focusing on integrated therapies and diagnostics. This methodology derisks its clinical trials. The company has an efficient “basket design” that allows for multiple data points, a big pipeline and an aggressive business development strategy. The company is Buy-rated with an $18/share price target. Risks include the potential need to raise additional cash by late 2017.

The overhauled information from the Phase 1 clinical trial discharged a month ago showed a general reaction rate of 79% (19/24) with extracranial strong tumors. What’s more, one patient with an astrocytoma (cerebrum tumor) had confirmation of considerable tumor relapse by volumetric estimation. Vitally, these reactions were seen in patients harboring NTRK, ROS1 and ALK revisions.

The reactions in patients with mind tumors are out and out wonderful, with numerous tumors appearing to “liquefy away”. The viability of the medication was highlighted amid the AACR presentation with a patient with stage IV non-little cell lung tumor (NSCLC) harboring a NTRK1 quality combination. He had metastatic illness to the cerebrum and had depleted all chemotherapies and was put in hospice.

To put it plainly, there was nothing else that should be possible. The patient was set on Entrectinib in March of 2015 and surprisingly accomplished an incomplete reaction in just 3 weeks with complete determination of all mind tumors. The patient stays on the medication today is still movement free after over a year. This case outlines the force of focused treatment.

Similarly as with all little top biotechs there are generous dangers that medications may not work out or miss out to rivalry. For instance, Entrectinib notwithstanding TRK quality combinations, targets ROS1 and ALK for which medications are as of now endorsed. Unless, they can separate themselves from these medications they could be constrained to the TRK market.

The budgetary circumstance of Ignyta is extremely steady. Subsequent to raising ~$60M prior this month in an offering, the organization has about $200 million in real money to bolster their clinical trial improvement. The money is very much required as the Phase 2 registrational trial as of now enlisting notwithstanding the progression of their pipeline will most likely eat money brisk. Taking after the late money raise administration estimated money close by is presently enough to see advancement of Entrectinib through endorsement, which is likely 2 years out.

Galena Biopharma (GALE:NASDAQ)

Galena Biopharma (GALE:NASDAQ)

Galena Biopharma (GALE:NASDAQ) has a business sector capitalization of$240M. Galena Biopharma’s NeuVax, a novel tumor immunization focusing on a worldwide business sector worth more than $5 billion ($5B), is being assessed in the Phase 3 PRESENT trial.

More than 70 occasions are foreseen in Q1/16, and between time results are normal in Q2/16. In light of examination of the clinical trial plan and past trial comes about, the study will probably be permitted to keep, making esteem for shareholders in the short term.

Galena Biopharma was among the greatest gainers on the Russell 2000 for Friday September 30 as the stock popped 6.64% to $0.35, speaking to an increase of $0.0218 per share. Exactly 1.94 million shares exchanged hands on 1,804 exchanges, contrasted and a normal every day volume of 7.17 million shares out of an aggregate buoy of 213.97 million. The stock opened at $0.33 and exchanged with an intraday scope of $0.35 to $0.32.

Galena Biopharma Inc. has had an exchanging range amongst $2.49 and $0.28 in the course of the most recent year, and it had a 50-day SMA of $0.41 and a 200-day SMA of $1.01.

ATR estimation of organization was 0.03 and Relative Strength Index (RSI) was 39.75. The stock instability for week was 7.47% while for month was 7.33%.The stock, starting last close, exchanged 21.57% to its 52 week low and was changed – 86.33% from its 52 week high. Beta variable, which measures the hazard of the security, was seen as 2.09. Hurricane’s quality Change from Open was at – 4.11% with a Gap of 2.90%.
Income per offer Details about GALE:

  • EPS development in recent year was 17.90%.
  • EPS development in one year from now is assessed to reach – 8.30% while EPS development gauge during the current year is set at – 5.90%.
  • The cost to deals proportion is 17.

Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Hemispherx Biopharma, Inc. (NYSEMKT:HEB) has been around for more than a couple of years and has had a rough and up to this point for the most part non-productive history. There have been a couple of noteworthy occasions for HEB since the start of 2015 that could change the long haul standpoint for speculators. In any case, it might be too soon to tell if that standpoint change will be certain, or if the organization will proceed on its long haul descending direction regardless of these progressions.

HEB finished restoring and overhauling their assembling office in New Jersey amid mid 2015. Nonetheless, they have not (yet) effectively made an attractive cluster of medication since the redesign was finished. Amid February 2016, HEB likewise experienced a critical and most likely long past due administration shake-up that is as yet settling out. It will tell whether this administration change will help the organization break out and push ahead, or whether this change will basically add up to a re-course of action of the deck seats on a sinking ship.

HEB has two essential items; their test drug competitor Ampligen, and the FDA affirmed Alferon N. HEB additionally has an option, trial type of their Alferon N drug proposed to be taken as a low measurements oral definition that may, or may not, give long haul advantage to shareholders. HEB like numerous little biopharmaceutical organizations stays in a to a great degree shaky money related circumstance with no dependable wellspring of money other than dilutive offers of stocks and different securities, or by means of amassing new obligation.

One thing specifically is vigilant before choosing whether to put a greater amount of my capital in HEB is the way they continue with their announcements in regards to the Zika infection, and whether they now move straightforwardly to start to address impasse that they have come to with the FDA on utilizing Ampligen as a treatment for CFS. The late moves in administration may purchase the organization a couple of months of breathing room with potential financial specialists, however it is dependent upon them to exploit that breathing room.

Fate Therapeutics Inc. (FATE:NASDAQ)

Fate Therapeutics Inc. (FATE:NASDAQ)

Fate Therapeutics Inc. (FATE:NASDAQ) has a $115M market capitalization and the organization is called as a shrouded diamond in the cell treatment space. Fate Therapeutics is growing little particles to balance/improve an assortment of cell sorts.

In view of the incited pluripotent immature microorganism (iPSC) stage, ensured by almost 30 issued licenses, and a versatile normal executioner (NK) cell innovation progressing in preclinical studies, the organization is working up a disease immunotherapy establishment. With lead competitor ProHema as of now in facility, growth immunotherapy resources for give upside, and a money position of $72.9M, Fate shares are prescribed to chance tolerant financial specialists.

Financial specialists unquestionably must be content with Fate Therapeutics and its fleeting execution. All things considered, the stock has bounced by 36.2% in the previous 4 weeks, and it is likewise over its 20 Day Simple Moving Average also. This is unquestionably a decent pattern, yet speculators are most likely asking themselves, would this be able to positive pattern proceed for FATE?

With the opening of enlistment in its Phase 1/2 clinical trial, the organization trust they are very much situated in 2016 to finish the underlying security appraisal and start assessing the capability of ProTmune for the aversion of life-debilitating immunological conditions, including intense GvHD, in disease patients experiencing allogeneic transplant for which there is a reasonable unmet and dire medicinal need.

Also, the plan to team up with the University of Minnesota in documenting an IND in the not so distant future for our Adaptive NK Cell malignancy immunotherapy, which has indicated relentless and intense tumor slaughtering autonomous of antigen acknowledgment in preclinical studies. We trust our allogeneic memory-like NK cell methodology is a novel and promising mediation technique for battling both fluid and strong tumors.”

FibroGen, Inc. (FGEN)

FibroGen, Inc. (FGEN)

FibroGen, Inc. (FGEN) is a Biopharmaceutical organization. Lead pipeline includes roxadustat, which is a hypoxia-inducible component prolyl hydroxylase (HIF-PH) inhibitor that fortifies erythropoiesis, directs iron digestion system, and decreases hepcidin. Basically, it kicks off the generation of red platelets by imitating the body’s reaction to high elevations. As an oral treatment, roxadustat would be situated as a substitute for injectable weakness drugs.

As indicated by a 10-K recorded prior in the year, administration accepts roxadustat can revise weakness through a separated instrument of activity and supplant medications at present being used, for example, ESAs and IV iron. The organization likewise trusts roxadustat would see extra uptake outside the dialysis setting, as specialists wouldn’t need to buy and store injectable ESAs.

Additionally, roxadustat has demonstrated potential decreases in cardiovascular occasions to date in Phase 2 examines, also taking into account the lessening or end of other usually utilized drugs. Such advantages would indicate cost viability, making it more probable that the treatment would be generally embraced.

To give you a thought of the potential effect of the endorsement of roxadustat on the offer cost, 2013 worldwide ESA deals totaled $8.6 billion. Administration trusts key open doors for roxadustat will be in patients that are not right now served viably by ESAs, for example, those in the NDD-CKD (non-dialysis-subordinate perpetual kidney infection) populace with iron deficiency.

In the latest quarter, the organization reported net pay of $.39 per share, because of a $65 million forthright installment from its concurrence with AstraZeneca (NYSE:AZN) and a $10 million turning point installment from accomplice Astellas (OTCPK:ALPMY) (OTCPK:ALPMF).

With a business sector capitalization of around $1.2 billion, the organization reported $368.8 million cash available and administration trusts they’ll complete the year with more than $310 million.

All out working costs were $62.8 million for the quarter, which incorporated a non-money segment of $10.8 million ($8.4 million stock-based pay cost).

Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) is a rising California-based pharmaceutical organization that is creating EVK-001, a nasal splash detailing of metoclopramide, a prokinetic specialist (builds gut motility) for use in gastroparesis in ladies. The shares tumbled to a low of $1.52 a week ago in the wake of hitting a 52-week high of $11.11 after the organization declared that a crucial Phase 3 trial testing EVK-001 in ladies with gastroparesis did not meet its endpoint.

The administration communicated shock with the study comes about since the prior Phase 2 study was effective. In this article, we examine the study comes about and propose an imaginable way for the organization going ahead. Analysts consider the shares underestimated at this value level and are starting scope on Evoke Pharma with Buy rating and regular offer value target (inborn worth) = $6.11.

In ascertaining the potential future income from EVK-001 in treatment of gastroparesis in ladies in the U.S., we accepted that 35% of these patients have extreme indications, which may be perfect contender for the intranasal EVK-001.

Yearly cost of treatment was thought to be about $2500 per understanding, in accordance with certain other business intranasal pharmaceuticals. Piece of the overall industry of 5% was expected at 5 years after medication dispatch in 2017, and after that 3% yearly piece of the pie development till 2030, achieving 6.5% at top in 2030. We hazard balanced future anticipated incomes utilizing likelihood of EVK-001 achieving the business sector = 60%.

Dangers in the venture: The dangers are like those for any developing biotechnology organization with no critical income and depicted in our past reports. Different item hopefuls specified above might neglect to succeed in clinical trials, symptoms may restrict their utilization, administrative offices won’t not endorse them and social insurance safety net providers won’t not repay them. The organization requires to raise critical money to pay its obligation and build up its clinical projects. Future capital raise may weaken existing shareholders and put descending weight on the stock cost.

Shares of Eleven Biotherapeutics (EBIO)

Shares of Eleven Biotherapeutics (EBIO)

Shares of Eleven Biotherapeutics (EBIO) were higher on substantial exchanging volume in recent weeks as the Cambridge, MA-based biopharmaceutical organization consented to buy the private held organization Viventia Bio in an all-stock arrangement.

Eleven Biotherapeutics inks a concurrence with Canadian outfit Viventia Bio to procure the Winnipeg-based firm for 4,013,431 shares of recently issued EBIO basic stock.

Offering shareholders will likewise be qualified to get unspecified money installments in view of the accomplishment of specific points of reference identified with Viventia’s lead item hopeful Vicinium, a recombinant combination protein in Phase 3 advancement for the treatment non-muscle intrusive bladder growth.

Top-line information from the late-organize study are normal in H1 2018. In a Phase 2 trial, patients treated with Vicinium demonstrated a 40% complete reaction rate following three months of treatment with no medication related genuine unfavorable occasions watched.

The joined organization will keep on doing business as Eleven Biotherapeutics and exchange under the present image on NASDAQ. Viventia CEO Stephen Hurly will serve as President and CEO. Eleven President and CEO Abbie Celniker will remain an executive.

Miniaturized scale top Eleven Biotherapeutics is up 8% premarket on expanded volume because of its declaration that its restrictive authorizing manage Roche for IL-6 inhibitor EBI-031 has been finished.

Under the terms of the understanding, EBIO is qualified for get $30M in installments ($7.5M forthright and $22.5M from the FDA’s OK of the IND), up to $240M in points of reference and sovereignties on net deals.

Enteromedics (NASDAQ:ETRM)

Enteromedics (NASDAQ:ETRM)

Enteromedics (NASDAQ:ETRM) speculators began off the week with a dreadful notification from the organization. A 8-K was recorded on Monday morning, expressing that the organization was in receipt of a de-posting notice from Nasdaq. In particular, Enteromedics stock has fallen beneath the $1.00 mark for 30 continuous days.

ETRM is likely acquainted with the procedure, since the organization just experienced it at the end of 2015 and start of 2016. This time, the de-posting process has two segments. The second part is stockholder value that is beneath Nasdaq necessities.

The principal thing financial specialists need to do is to consider the obstacles that are before this organization, and that any de-posting process makes exploring and clearing these obstacles significantly more troublesome. You don’t have to prosecute the vBloc item to make such an appraisal. Separate your sentiments about the item from your emotions about the value. At this stage, vBloc could be an item that can convey better than average achievement, yet the value would at present be frustrated.

The last time the organization got a de-posting notice, the arrangement was a 1-for-15 reverse split with the stock exchanging at $0.12 per offer. That brought the stock up to $1.80 per share and recovered the organization into consistence. From that point forward, the stock has tumbled to $0.57 per share and has dropped out of consistence once more.

To place this in context, consider that if the past converse split had not happened, this stock would exchange at under $0.04 per offer.

Numerous financial specialists who stay in this value have officially discounted the possibility that present administration can adequately showcase the item. Nowadays, the mantra of the bull proposal is that the innovation and items will be purchased by another element, and when that happens, the prize to shareholders will be considerable.

Shares of business biomaterial organization Amedica Corp (AMDA)

Shares of business biomaterial organization Amedica Corp (AMDA)

Shares of business biomaterial organization Amedica Corp (AMDA) are taking off more than 33% after they declared a dispersion manage Shandong Weigao Orthopedic Device Company Limited.

Under the assention, Amedica’s silicon nitride spinal inserts will be solely showcased and conveyed in China where Weigao Orthopedic is based. The orthopedic organization will make yearly buys of 20,000 units in the main year and extend to 50,000 units by the 6th year, taking after administrative endorsement by the China Food and Drug Administration (CFDA).

“With more than 50,000 least unit deals to happen inside the initial two years taking after CFDA leeway, this understanding far surpasses all out silicon nitride unit deals to-date, and denote a pivotal time for Amedica,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “This organization with Weigao Orthopedic permits us to essentially expand our worldwide deals impression with a vast scale appropriation accomplice who is acquainted with the Chinese administrative scene.”

“We are exceptionally satisfied with this selective merchant organization as we plan to influence the Amedica brand to offer a really separated item to our wide system of healing facilities and restorative units in China,” expressed Mr. Gong Jianbo, Chief Executive Officer and Executive Director of Weigao Orthopedic. “We expect the mix of this actually progressed biomaterial with our settled system to rapidly increase noteworthy piece of the overall industry.

Amedica also gained 9% on robust volume in response to its announcement that the FDA has approved expanded sizes of its Valeo II Lateral Lumbar interbody fusion device. The new offerings, designed to accommodate a wider range of anatomies while delivering greater stability, will be commercially available next week.

NASDAQ: AKBA Akebia Therapeutics Looks Strong, But Risks are Also There

NASDAQ: AKBA Akebia Therapeutics Inc Stock

Akebia’s key item being developed is Vadadustat, orally regulated inhibitor of hypoxia-initiating component prolyl hydroxylase (HIF-PH) protein which is being tried in two Phase 3 trials in non-DD, CKD and DD-CKD patients. Hindrance of this protein recreates the physiological impacts of high height, consequently expanding erythropoietin discharge and expanding red platelet generation. At present, the backbone of treatment in iron deficiency with CKD is an organization of ESAs which are costly and are connected with antagonistic symptoms like the expanded danger of thromboembolism and stroke.

CKD patients on ESAs may likewise require intravenous iron supplementation. Intravenous iron has symptoms like extreme touchiness responses and gastritis, and furthermore, numerous CKD patients may get to be lethargic to ESAs. Numerous CKD patients with paleness, particularly those not on dialysis are undertreated for pallor. Vadadustat is controlled once day by day orally (not at all like subcutaneous ESA infusions).

Vadadustat additionally has other potential advantages over ESAs; for instance, it might maintain a strategic distance from the requirement for supplemental iron treatment and the erythropoietin levels delivered in light of the medication have a typical physiological circadian mood not at all like the abnormal states seen with ESAs (which are connected with unfriendly thromboembolic and cardiovascular occasions). Contrasted with other HIF-PH inhibitors being developed, Which is all the more particularly focused at HIF-2 alpha.

Akebia’s principal rival is Fibrogen (NASDAQ: FGEN). Fibrogen’s HIF-PH program (roxadustat) was authorized by AstraZeneca (NYSE:AZN) in the U.S., China some different markets. Fibrogen additionally authorized the medication to Astellas in the E.U., South Africa, Middle East and some different markets. Fibrogen’s licenses for roxadustat were repudiated in aggregate in Europe and a section in the U.S. Furthermore, Japan, therefore giving Akebia licensed innovation advantage.

The organization may require more money to forward its R&D programs requiring obligation and/or value financing that may put descending weight on the normal stock. Akebia likewise has a progressing patent question with Fibrinogen over HIF-PH inhibitors. Akebia has gotten positive managing so far in the progressing patent question yet it is conceivable that it might get an antagonistic choice later on.

Disclaimer

DISCLAIMER / TERMS AND CONDITIONS OF USE

INVESTORS SHOULD READ THIS DISCLAIMER

Who owns and controls the website located at https://Awesomepennystocks.com

The website located at https://awesomepennystocks.com (the Website) is owned by Market News  LLC. The Website, its owner, affiliates, control persons, directors, officers, employees and agents are hereafter collectively referred to as the “Publisher”, “we”, “us” or “ours”.

What do we do?

We are paid advertisers, also known as stock touts or stock promoters who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”).

How is the Information published?

We publish the Information on the Website, in newsletters, audio, and live interviews featured reports message boards and email communications for specific time periods that are agreed upon between us and the Profiled Issuer. Our publication of the Information is known as a “Campaign”.

Will everyone receive the Information at the same time?

No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.

How is a potential investor impacted if they receive the Information later than other investors?

If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.

What will happen when the Campaign ends?

Most, if not, all of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide variations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will likely lose most, if not, all of their investment.

Why do we publish only favorable Information?

We only publish favorable information because we are compensated to only publish favorable information.

Why don’t we publish negative information?

We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.

Is the Information complete, accurate, truthful or reliable?

The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one sided and not balanced, complete, accurate, truthful or reliable.

What we do not do?

We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence or research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

Where does the Information come from?

The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources.

What will happen if an investor relies on the Information?

The Information is neither a solicitation to buy nor an offer to sell securities. The Information should not be used to make an investment decision or for trading or investment purposes. If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not, all of his or her investment.

Who pays us to publish the Information?

The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.

The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”.

What warranties do we make about the Information?

None. We make no warranty or representation about the Information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

Who is responsible if an investor relies on the Information?

The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information. A person’s review and/or reliance upon the Information is at their own risk. We are not responsible for omissions or errors in the Information. We will not update the Information and we are not responsible for actions taken by any person who relies upon the Information.

What do we urge potential investors to do?

Investors should conduct their own in-depth investigation of the Profiled Issuers with the assistance of his or her legal, tax and investment advisors. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information you and your advisors deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information you receive directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.

Why is this Disclaimer being provided?

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 ( the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (“the “Securities Act”), to specifically disclose our compensation to you as well as other information including that we may hold, as well as purchase and sell the securities of a Profiled Issuer before, during and after we publish the Information about the Profiled Issuer. We may instruct investors to purchase the securities of a Profiled Issuer during the same time that we sell.

The anti-fraud provisions of state and federal securities laws require us to inform you that we will engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

What we are not?

We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:

  • An independent advisor or consultant;
  • Providing investment advice;
  • Acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • Broker-dealer activities or acting in the capacity of a registered representative or broker;
  • Stock picker;
  • Securities trading expert;
  • Securities researcher or analyst;
  • Financial planner or financial planning;
  • Provider of stock recommendations;
  • Provider of advice about buy and sell or hold recommendations as to specific securities; or
  • Making an offer or sale of securities or solicitation to purchase securities.

What conflicts of interest do we have in publishing the Information?

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:

  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities including those who engage our services and/or compensate us will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.

What are some of the risks that investors should be aware of?

Any investment in the Profiled Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers includes, but is not limited to the risks stated below.

  • The Information is not a solicitation or recommendation to buy, sell or hold securities and we do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information is material or non-material making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • When the Campaign ends, the securities of a Profiled Issuer will decline dramatically.
  • If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative ; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
  • The Information contains forward looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made and we do not undertake to update forward looking statements that may change at any time.
  • The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com (See section below titled Risks Related to the Profiled Issuers, which provides additional information pertaining thereto).
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer even where such compensation is not disclosed by them.
  • By reading the Information you agree to indemnify and hold us harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information.

Risks Related to the Profiled Issuers?

  • We do not provide you with all of the risks related to the Profiled Issuers and to understand such risks you must conduct your own due diligence with the assistance of your legal, tax and investment advisor.
  • Any investment in a Profiled Issuer’s securities is high risk. If you invest in the securities of a Profiled Issuer you could lose your entire investment.
  • The continued operations and future prospects of a Profiled Issuer may be dependent upon receiving adequate financing which they may be unable to obtain.
  • If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or OTC Market’s Pink Sheet quoted company may be delinquent in its Pink Sheet reporting obligations as reported by the OTC Markets News Service’s or OTC Markets posting a negative sign pertaining to the Profiled Issuer at www.pinksheets.com, as follows: (i) Limited Information for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) Pink Sheets – No Information, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) Caveat Emptor, signifying Buyer Beware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
  • Often the Profiled Issuers are development stage companies with little or no operations, and their securities should be considered extremely speculative for investment purposes.
  • The Profiled Issuers are negatively affected by the current economic downturn and may have a lack of adequate financing to meet their operating expenses, operational goals and expansion plans.
  • The Profiled Issuers may have inadequate financing to pursue their operational plans and support their ongoing operations.

Risks Related to buying the securities of the Profiled Issuers?

  • The Information may recommend that investors purchase a Profiled Issuer’s shares while we sell securities of the same Profiled Issuer which will likely cause investors to suffer losses.
  • We may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • The Information may instruct investors to buy a Profiled Issuer’s securities so that the person who hires and compensates us can sell their own shares which may cause you to suffer a loss of part or all of your investment.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.

Are risks in this disclaimer the only risks investors should be aware of?

No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax adviser prior to purchasing the securities of any Profiled Issuer.